These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24491811)

  • 21. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
    Dumas de la Roque E; Savineau JP; Bonnet S
    Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium channels in pulmonary arterial hypertension.
    Boucherat O; Chabot S; Antigny F; Perros F; Provencher S; Bonnet S
    Eur Respir J; 2015 Oct; 46(4):1167-77. PubMed ID: 26341985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
    Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathology and pathobiology of pulmonary hypertension.
    Guignabert C; Dorfmuller P
    Semin Respir Crit Care Med; 2013 Oct; 34(5):551-9. PubMed ID: 24037624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
    Evans CE; Cober ND; Dai Z; Stewart DJ; Zhao YY
    Eur Respir J; 2021 Sep; 58(3):. PubMed ID: 33509961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathology and aspects of pathogenesis in pulmonary arterial hypertension.
    Dorfmüller P; Humbert M; Capron F; Müller KM
    Sarcoidosis Vasc Diffuse Lung Dis; 2003 Mar; 20(1):9-19. PubMed ID: 12737275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
    Waxman AB; Zamanian RT
    Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niflumic Acid Attenuated Pulmonary Artery Tone and Vascular Structural Remodeling of Pulmonary Arterial Hypertension Induced by High Pulmonary Blood Flow In Vivo.
    Wang K; Ma J; Pang Y; Lao J; Pan X; Tang Q; Zhang F; Su D; Qin S; Shrestha AP
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):383-91. PubMed ID: 26132368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic assessment of vasculopathies in pulmonary hypertension.
    Pietra GG; Capron F; Stewart S; Leone O; Humbert M; Robbins IM; Reid LM; Tuder RM
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):25S-32S. PubMed ID: 15194175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metabolic theory of pulmonary arterial hypertension.
    Paulin R; Michelakis ED
    Circ Res; 2014 Jun; 115(1):148-64. PubMed ID: 24951764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
    Zhao YD; Courtman DW; Deng Y; Kugathasan L; Zhang Q; Stewart DJ
    Circ Res; 2005 Mar; 96(4):442-50. PubMed ID: 15692087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapies and future directions in pulmonary arterial hypertension.
    Gurtu V; Michelakis ED
    Can J Cardiol; 2015 Apr; 31(4):489-501. PubMed ID: 25840098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of oxidized lipids in pulmonary arterial hypertension.
    Sharma S; Ruffenach G; Umar S; Motayagheni N; Reddy ST; Eghbali M
    Pulm Circ; 2016 Sep; 6(3):261-73. PubMed ID: 27683603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting PDGF pathway in pulmonary arterial hypertension.
    Antoniu SA
    Expert Opin Ther Targets; 2012 Nov; 16(11):1055-63. PubMed ID: 22924478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New progress in diagnosis and treatment of pulmonary arterial hypertension.
    Zhang ZQ; Zhu SK; Wang M; Wang XA; Tong XH; Wan JQ; Ding JW
    J Cardiothorac Surg; 2022 Aug; 17(1):216. PubMed ID: 36038916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension.
    Berghausen E; ten Freyhaus H; Rosenkranz S
    Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.
    Jurasz P; Courtman D; Babaie S; Stewart DJ
    Pharmacol Ther; 2010 Apr; 126(1):1-8. PubMed ID: 20117135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deficiency of NOX1/nicotinamide adenine dinucleotide phosphate, reduced form oxidase leads to pulmonary vascular remodeling.
    Iwata K; Ikami K; Matsuno K; Yamashita T; Shiba D; Ibi M; Matsumoto M; Katsuyama M; Cui W; Zhang J; Zhu K; Takei N; Kokai Y; Ohneda O; Yokoyama T; Yabe-Nishimura C
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):110-9. PubMed ID: 24233492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.
    McMurtry MS; Archer SL; Altieri DC; Bonnet S; Haromy A; Harry G; Bonnet S; Puttagunta L; Michelakis ED
    J Clin Invest; 2005 Jun; 115(6):1479-91. PubMed ID: 15931388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.